Northwire Canada EditionSaturday, July 18, 2026
Sign inSubscribe
Northwire
⌕
AII 19.25 +3.9% GGA 5.95 +12.3% VM 0.140 +3.7% GSR 0.365 +1.4% QCX 0.195 +0.0% EAU 0.085 +0.0% MCM 0.310 +0.0% BAT 0.100 +5.3% SFR 0.370 +68.2% FFU 0.125 +4.2% TVI 0.045 −10.0% ZNX 0.080 +0.0% TSK 1.06 +0.9% OMM 0.050 +0.0% EMO 0.320 −7.2% MDM 0.060 +0.0% AII 19.25 +3.9% GGA 5.95 +12.3% VM 0.140 +3.7% GSR 0.365 +1.4% QCX 0.195 +0.0% EAU 0.085 +0.0% MCM 0.310 +0.0% BAT 0.100 +5.3% SFR 0.370 +68.2% FFU 0.125 +4.2% TVI 0.045 −10.0% ZNX 0.080 +0.0% TSK 1.06 +0.9% OMM 0.050 +0.0% EMO 0.320 −7.2% MDM 0.060 +0.0%
M&A / Property

BriaCell Announces Collaboration with MSK Accelerator to Advance Bria-OTS+(TM) for Breast Cancer

By The Northwire Desk — AI Analysis Oct 21, 2025 · 07:30 BCT · 17.08 BRIACELL THERAPEUTICS CORP. J
BCT · Price

Executive Summary

  • BriaCell Therapeutics announced a strategic collaboration with Memorial Sloan Kettering Cancer Center’s (MSK) Therapeutics Accelerator program to accelerate development of its Bria‑OTS+ platform.
  • The partnership will provide manufacturing, IND preparation and submission, and clinical protocol support for a Phase 1 trial of Bria‑BRES+, the breast‑cancer candidate within the Brata‑OTS+ platform.
  • Access to MSK’s clinical expertise is expected to expedite multi‑indication development (breast, prostate, and other cancers) and potentially enhance the commercial prospects of BriaCell’s off‑the‑shelf personalized immunotherapies.

Key Details

  • Collaboration Scope: Manufacturing support, IND development, and clinical protocol assistance for Phase 1 trial of Bria‑BRES+ (breast cancer).
  • Platform Focus: Bria‑OTS+ – next‑generation personalized off‑the‑shelf immunotherapy platform targeting multiple tumor types (metastatic breast, prostate, etc.).
  • Program Expansion: Builds on BriaCell’s prior selection into MSK’s Therapeutics Accelerator Cohort.
  • Key Personnel Quotes:
  • Dr. William V. Williams, President & CEO – highlighted the unmet need in metastatic breast cancer and enthusiasm for the partnership.
  • Miguel Lopez‑Lago, PhD, Chief Scientific Officer – emphasized acceleration of platform development.
  • Shanu Modi, MD, Breast Medical Oncologist at MSK – noted importance of collaborations to translate innovations into patient treatments.
  • Financial Interests: MSK holds institutional financial interests related to BriaCell (disclosed).
  • Forward‑Looking Statements: The release contains typical forward‑looking language regarding anticipated benefits and timelines; no guarantee of outcomes.

Notable Quotes

“We are thrilled to collaborate with MSK’s scientific and clinical experts to address the urgent unmet medical need of many thousands of metastatic breast cancer patients.” – Dr. William V. Williams, President & CEO, BriaCell

“This collaboration with MSK will accelerate the development of our advanced personalized off‑the‑shelf immunotherapy platform, Bria‑OTS+, which we believe has the potential to transform cancer care…” – Miguel Lopez‑Lago, PhD, Chief Scientific Officer, BriaCell

Read the original news release →

More from BRIACELL THERAPEUTICS CORP. J

Jun 25, 2026 · 07:30

BriaCell Partners with Uneedle for Scalable Microneedle Administration of Bria-IMT(TM)

M&A / Property Jun 02, 2026 · 16:05

BriaCell Closes $4.7M Discounted Offering as Pre-Revenue Burn Rate Demands Cash, Dilution Weighs on Sentiment

Financings Jun 01, 2026 · 07:30

BriaCell’s ASCO Data Validates Pipeline Trajectory, But Dilutive Capital Raise and Phase 3 Event-Driven Timeline Keep Near-Term Upside Capped

Other May 31, 2026 · 19:59

BriaCell Therapeutics Announces Pricing of Offering

Financings May 31, 2026 · 03:20

Briacell prices shares of $4.7M offering at $3.25 each

Financings May 26, 2026 · 07:30

Safety Confirmed but Efficacy Uncertainty Weighs on Valuation Amidst Dilution Concerns

Other